Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LTRN 
Lantern Pharma Inc (LTRN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: LTRN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22
1 Year Target Price $22
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.22% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 33.97M USD | Price to earnings Ratio - | 1Y Target Price 22 |
Price to earnings Ratio - | 1Y Target Price 22 | ||
Volume (30-day avg) 2 | Beta 1.54 | 52 Weeks Range 2.55 - 6.12 | Updated Date 07/2/2025 |
52 Weeks Range 2.55 - 6.12 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.84 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -43.68% | Return on Equity (TTM) -75.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14553011 | Price to Sales(TTM) - |
Enterprise Value 14553011 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.21 | Shares Outstanding 10784700 | Shares Floating 8187655 |
Shares Outstanding 10784700 | Shares Floating 8187655 | ||
Percent Insiders 14.1 | Percent Institutions 21.49 |
Upturn AI SWOT
Lantern Pharma Inc
Company Overview
History and Background
Lantern Pharma Inc. was founded in 2013 and is focused on leveraging artificial intelligence (AI) and machine learning to accelerate and de-risk the development of precision oncology therapeutics. The company has built an AI platform, RADRu00ae, that analyzes data to identify patients most likely to benefit from its drug candidates.
Core Business Areas
- Drug Development: Lantern Pharma focuses on developing targeted therapies for cancer patients by utilizing its AI platform to identify drug candidates and predict patient response.
- RADRu00ae Platform: Offers an AI-driven platform used for drug repurposing, patient stratification, and predictive biomarker identification.
- Commercialization: Commercializing therapeutic assets in oncology indications with unmet needs
Leadership and Structure
Panna Sharma is the President and CEO. The company has a board of directors overseeing strategic direction. Operations are structured around drug development programs and the RADRu00ae AI platform.
Top Products and Market Share
Key Offerings
- LP-100 (Tavocepient): A small molecule drug candidate being developed for various solid tumors, including non-small cell lung cancer and pancreatic cancer. Lantern Pharma's competitive advantage includes the RADRu00ae platform which allows for patient stratification for LP-100. Competitors developing treatments for similar cancers include AstraZeneca, Roche, and Merck. Market share is currently negligible pending regulatory approval.
- LP-284: A DNA damaging agent being developed for blood cancers and solid tumors. Competitors developing similar treatments include Bristol Myers Squibb and AbbVie. Market share is currently negligible pending regulatory approval.
- LP-300: A drug candidate in clinical development for never smokers with non-small cell lung cancer (NSCLC). RADR platform predicts likely responders. Competing with other NSCLC therapies from companies like Roche and Merck. Market share is currently negligible pending regulatory approval.
Market Dynamics
Industry Overview
The oncology therapeutics market is a large and rapidly growing market driven by aging populations, increasing cancer incidence, and advances in cancer diagnosis and treatment. Precision oncology is becoming increasingly important.
Positioning
Lantern Pharma is positioned as a precision oncology company leveraging AI and machine learning to develop targeted therapies and improve patient outcomes. Its competitive advantage lies in its RADRu00ae platform and its ability to identify patients most likely to respond to its drug candidates.
Total Addressable Market (TAM)
The global oncology market is estimated to reach over $400 billion in the coming years. Lantern Pharma is aiming to capture a portion of this market by developing targeted therapies for specific patient populations identified through its RADRu00ae platform.
Upturn SWOT Analysis
Strengths
- Proprietary RADRu00ae AI platform
- Focus on precision oncology
- Experienced management team
- Targeted therapeutic approach
Weaknesses
- Limited financial resources
- Early-stage drug development
- Reliance on AI predictions
- Lack of approved products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of RADRu00ae platform capabilities
- Successful clinical trial outcomes
- FDA approvals for drug candidates
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- AI algorithm limitations
Competitors and Market Share
Key Competitors
- MRNA
- ONCT
- CRSP
- EDIT
Competitive Landscape
Lantern Pharma's competitive advantage lies in its AI-driven platform for precision oncology. However, it faces significant competition from larger pharmaceutical and biotechnology companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancements in its RADRu00ae platform and progress in its drug development pipeline.
Future Projections: Future growth depends on successful clinical trials, FDA approvals, and potential partnerships.
Recent Initiatives: Focusing on expanding the RADRu00ae platform, advancing clinical trials for lead drug candidates, and seeking strategic partnerships.
Summary
Lantern Pharma is a pre-revenue, early-stage biotech company leveraging AI for precision oncology. Its strength is its RADRu00ae platform and targeted drug development, but its weaknesses include limited financial resources and reliance on clinical trial success. It must capitalize on partnership opportunities and manage clinical trial risks carefully. Overall, it shows potential but remains a high-risk investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. It is based on publicly available information and current market conditions, which are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lantern Pharma Inc
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2020-06-11 | President, CEO & Director Mr. Panna Sharma | ||
Sector Healthcare | Industry Biotechnology | Full time employees 24 | Website https://www.lanternpharma.com |
Full time employees 24 | Website https://www.lanternpharma.com | ||
Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.